45.85
Precedente Chiudi:
$46.43
Aprire:
$46.51
Volume 24 ore:
296.92K
Relative Volume:
0.34
Capitalizzazione di mercato:
$2.99B
Reddito:
$58.89M
Utile/perdita netta:
$-240.88M
Rapporto P/E:
-14.79
EPS:
-3.1
Flusso di cassa netto:
$-239.96M
1 W Prestazione:
-1.08%
1M Prestazione:
-2.74%
6M Prestazione:
+3.36%
1 anno Prestazione:
+6.93%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Confronta KYMR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KYMR
Kymera Therapeutics Inc
|
45.85 | 3.26B | 58.89M | -240.88M | -239.96M | -3.10 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-03 | Ripresa | Morgan Stanley | Overweight |
2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
2025-05-20 | Ripresa | Stifel | Buy |
2025-03-13 | Iniziato | Citigroup | Buy |
2024-12-10 | Iniziato | BTIG Research | Buy |
2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2024-11-18 | Iniziato | Stephens | Overweight |
2024-09-09 | Ripresa | Leerink Partners | Outperform |
2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
2024-04-22 | Iniziato | Oppenheimer | Outperform |
2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2023-06-30 | Iniziato | Truist | Buy |
2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
2022-11-08 | Iniziato | Raymond James | Mkt Perform |
2022-08-15 | Iniziato | Jefferies | Buy |
2022-08-03 | Iniziato | Goldman | Buy |
2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
2022-04-28 | Iniziato | Credit Suisse | Outperform |
2022-03-10 | Iniziato | JP Morgan | Neutral |
2022-02-10 | Iniziato | Wells Fargo | Overweight |
2021-09-30 | Iniziato | B. Riley Securities | Neutral |
2021-09-30 | Iniziato | Stifel | Buy |
2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
2021-05-21 | Iniziato | UBS | Buy |
2021-04-14 | Iniziato | Berenberg | Buy |
2020-12-04 | Iniziato | H.C. Wainwright | Buy |
2020-09-15 | Iniziato | BofA Securities | Neutral |
2020-09-15 | Iniziato | Cowen | Outperform |
2020-09-15 | Iniziato | Guggenheim | Buy |
2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Will Kymera Therapeutics Inc. stock benefit from AI tech trendsOutstanding trading profits - jammulinksnews.com
What drives Kymera Therapeutics Inc. stock priceDouble-digit growth - Autocar Professional
Is Kymera Therapeutics Inc. a good long term investmentFree Stock Market Query - Autocar Professional
What analysts say about Kymera Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com
Kymera Therapeutics Inc. Stock Analysis and ForecastExplosive capital appreciation - jammulinksnews.com
What makes Kymera Therapeutics Inc. stock price move sharplyAlpha Stock Ideas - beatles.ru
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance
Goldman Sachs Initiates Coverage on Kymera Therapeutics as Early-Stage Biotech with Potential Upside of 33.75% - AInvest
How Kymera Therapeutics Inc. stock performs during market volatilityFree Risk Assessment Services - Newser
Forecasting the Future: Targeted Protein Degradation - openPR.com
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating - Insider Monkey
Kymera Therapeutics shares fall 1.26% intraday amid Gilead Sciences' clinical hold on HIV treatment trials. - AInvest
Kymera Therapeutics stock price target lowered to $65 at Brookline Capital - Investing.com Canada
(KYMR) Investment Analysis - news.stocktradersdaily.com
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion - Investing.com Canada
Kymera Therapeutics (KYMR) director group buys $13.9 million in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics: Baker Bros acquire $28.8m in shares By Investing.com - Investing.com South Africa
Kymera Therapeutics: Baker Bros acquire $28.8m in shares - Investing.com
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN
Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) - GuruFocus
KYMR: Key Insights on Recent Developments | KYMR Stock News - GuruFocus
Nuclear stocks, Kymera Therapeutics, Estee Lauder - TradingView
Gilead and Kymera in pact to develop cancer drugs - MSN
Kymera Therapeutics (KYMR) Target Price Lowered by Wells Fargo | KYMR Stock News - GuruFocus
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update - TradingView
Kymera Therapeutics launches $250 million public stock offering - Investing.com
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - PharmaLive
Gilead (GILD) Enters Agreement with Kymera to Enhance Cancer Tre - GuruFocus
Kymera Therapeutics (KYMR) Advances IRAK4 Partnership with Sanofi | KYMR Stock News - GuruFocus
Gilead and Kymera in pact to develop cancer drugs (GILD) (KYMR) - Seeking Alpha
Gilead (GILD) Enters Agreement with Kymera for Novel Cancer Trea - GuruFocus
When (KYMR) Moves Investors should Listen - news.stocktradersdaily.com
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):